Among the new cardiovascular criteria are three evidence-based medications for heart failure, i.e. spironolactone when eGFR > 30 ml/min (B7), SGLT2 when symptomatic (B8), and sacubitril/valsartan when there is persisting failure in the presence of reduced ejection fraction (B9, with angiotensin-converting-enzyme inhibitors (ACEI) withdrawal). The gene discussed is SLC5A2; the disease is heart failure.